BioIVT, a leading global provider of biospecimens, cell and gene therapy related products, and research models and services for drug development purposes, today announced the promotion of Richard Haigh, PhD, to Chief Executive Officer (CEO) effective August 1.
Dr. Haigh joined BioIVT in May 2022 as Chief Operating Officer and brings over 27 years' experience in the life science research and diagnostics space covering products, consumables, and services, including over 15 years with Thermo Fisher Scientific/Life Technologies.
"I am delighted and honored to be taking on the CEO role at BioIVT during this exciting time. BioIVT is a fantastic mission driven business focused on enabling our customers to more efficiently and effectively develop new therapeutics that save lives. We have a tremendous runway ahead of us with multiple avenues for continued growth, and I am excited by the opportunity to contribute to this organization," said incoming CEO Dr. Haigh.
Former CEO Jeff Gatz who is retiring from day-to-day involvement with BioIVT will continue to support the company as an advisor focused on M&A and business development activities. Over the last 26 years, Gatz has successfully led and grown the business from a small family operation to a global enterprise employing over 500 people and serving thousands of pharma, biotech, CRO and diagnostic customers worldwide.
Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options
Merck partners with California-based research group to study catalysis innovation through machine learning
Philips and Masimo introduce advanced monitoring capabilities to Philips high acuity patient monitors
Subscribe To Our Newsletter & Stay Updated